If new leadership were all a beleaguered drugmaker needed to revive its operations, the pharmaceutical sector would be a very different place. Yesterday, shares of Sanofi-Aventis
After a positive 2007 that saw Sanofi and partner Bristol-Myers Squibb
Sanofi's new CEO, arriving in December, is Chris Viehbacher, the former head of GlaxoSmithKline's
Glaxo also emphasized this renewed focus on emerging markets when it performed its own CEO shuffle back in May. To better reach these markets, and expand its generic-drug operations, Sanofi has been trying to acquire the shares it doesn't already own of Czech drugmaker Zentiva, much like Barr Pharmaceuticals'
While some investors may be cheering Sanofi's management shakeup, a new CEO alone cannot cure the generic-drug issues that plague both this company and rivals such as Pfizer